Indefinite Delivery Contract SPE2DX15D9248

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued up to $4,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities. The contract, designated SPE2DX, covers the delivery of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables such as injections, tablets, creams, auto-injectors, and specialty medications. DMS Pharmaceutical Group holds this IDC through November 2026, which enables DLA to issue firm fixed-price delivery orders for various pharmaceutical items as needed. The company has demonstrated its capability to deliver a diverse portfolio of pharmaceutical products to the DLA, including specialized medications like Xolair, Trikafta, Keytruda, Botox, and Nucala. The contract does not utilize any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.

The provided task orders under the IDC indicate that DMS Pharmaceutical Group is delivering a wide variety of pharmaceutical products to DLA, including contraceptives, hormonal therapies, vaccines, anesthetics, and other specialized medications. The firm fixed-price delivery orders range in value from several hundred dollars to over $5,000, covering items such as NEXPLANON implants, ACTEMRA syringes, ROTATEQ vaccine, and PROGESTERONE capsules. The place of performance for these task orders is DMS Pharmaceutical Group's facility in Park Ridge, Illinois.